Stock market performance data from financial news sources like Bloomberg, Reuters, or Yahoo Finance

Eli Lilly's Tirzepatide Zepbound Cuts Diabetes Risk by 94%, Achieves 23% Weight Loss

Aug 20, 2024, 11:00 AM

Eli Lilly's weight loss drug, Zepbound, featuring tirzepatide, has demonstrated significant efficacy in reducing the risk of developing type 2 diabetes. In a long-term study, the drug reduced the risk by 94% in adults with pre-diabetes and obesity or overweight, compared to a placebo. The three-year SURMOUNT-1 trial also showed that patients on the highest dose of Zepbound lost an average of 23% of their body weight over 176 weeks. These findings bolster the case for the drug's long-term use in managing obesity and preventing diabetes. The study's results have positively impacted Eli Lilly's stock performance, with shares seeing a pre-market increase.